Laura Panjwani

Mark Levis, MD, PhD, highlights the promise and potential challenges of the FLT3-inhibitor quizartinib in acute myeloid leukemia.

FLT3 targeted agents are emerging in the treatment of acute myeloid leukemia, and which specific agent will be most effective is highly dependent on whether a patient has been previously treated.

Robert G. Uzzo, MD, discusses the promise of immunotherapies as well as the challenges with using them across different indications in renal cell carcinoma.

Immunotherapy combinations have significant potential as treatment for patients with renal cell carcinoma.

It’s not often that oncologists get to be the first to utilize cutting-edge technology.

Tyrosine-kinase inhibitors have considerably improved survival outcomes for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

Results from the phase III PALOMA-2 study—which demonstrated a significant progression-free survival advantage with palbociclib (Ibrance) plus letrozole compared with letrozole alone in ER-positive, HER2-negative metastatic breast cancer—were recently published in The New England Journal of Medicine.

While resistance to EGFR-targeted therapies in non–small cell lung cancer presents a major challenge, there is a silver lining.

There are a wide variety of novel agents currently being investigated in the neoadjuvant setting for patients with HER2-positive breast cancer.

Alan P. Venook, MD, discusses key issues in metastatic colorectal cancer, including tumor sidedness and the conflicting data regarding the precise benefit of cetuximab in the frontline setting.

For a long time, patients with metastatic colorectal cancer had poor outcomes and very limited treatment options, said Tanios Bekaii-Saab, MD.

Therapeutic options for patients with renal cell carcinoma have increased rapidly in the past decade, yet the field is still poised to expand significantly in the coming years, said Robert S. Alter, MD.

Women who have been vaccinated against HPV can undergo less-intensive cervical cancer screening than is currently recommended, according to new findings released from the Harvard T.H. Chan School of Public Health.

Researchers have identified 3 distinct molecular subtypes of primary prostate cancer that correlate with distant metastasis-free survival and response to radiation therapy.

There has been renewed optimism in hepatocellular carcinoma with regorafenib, a novel second-line agent that is currently being considered for approval by the FDA.

Hepatocellular carcinoma‎ incidence continues to rise among patients with hepatitis B despite improvements in antiviral therapies, stressing the importance of screening and surveillance in this population.

The combination of nilotinib and trametinib proved to be synergistic in BRAF/NRAS wild-type melanoma.

Results of a new study found that less than half of patients with advanced cervical cancer are receiving all 3 of the therapies considered standard of care for the disease: external beam radiation therapy, brachytherapy, and chemotherapy.

The combination of atezolizumab and cobimetinib may lead to a higher overall response and a longer progression-free survival than either agent alone in patients with metastatic melanoma.

Enrolling clinical trials can be a long process, especially in rare diseases with limited patient populations. This is a particularly significant issue for patients with anaplastic thyroid cancer, an extremely rare and aggressive disease.

Sundar Jagannath, MD, discusses the importance of the standardization of a 3-drug regimen for newly diagnosed multiple myeloma, how the regimen may evolve going forward, and other novel agents on the horizon.

Lajos Pusztai, MD, DPhil, discusses findings that suggest it is unlikely that any single gene can predict response to targeted therapy for patients with HER2-positive breast cancer.

While immunotherapy is currently only beneficial in select cancers, it is possible for this type of treatment to eventually work for all patients.

Immunotherapy has been a game changer in oncology, improving survival and providing long, durable responses in melanoma, lung, head and neck cancer, and others.

The treatment paradigm of advanced renal cell carcinoma (RCC) has been rapidly changing. First, the FDA approved the combination of lenvatinib and everolimus in May 2016 as a treatment for patients with advanced RCC following prior antiangiogenic therapy.

Suzanne L. Topalian, MD, discusses the development of PD-1/PD-L1 inhibitors, emerging biomarkers, and why a precision medicine approach is necessary to identify effective immunotherapy combination regimens.

Mutation discordance between primary and metastatic sites in colorectal cancer may occur more often than previously understood, opening the door for potential new therapeutic approaches to treating the disease.

The correlation between tumor location and improved survival varies based on stage of disease in patients with metastatic colorectal cancer.

Jason Luke, MD, discusses some of the exciting research that is happening across the field of immunotherapy in melanoma, including combination strategies, novel agents, and next-generation diagnostics.

The field of sarcoma may have reached a turning point, according to Kiran K. Turaga, MD.